Global Rare Hemophilia Factors Market 2022-2026

希少血友病因子のグローバル市場2022-2026:新鮮凍結血漿、濃縮因子、クリオプレシピテート、その他

◆タイトル:Global Rare Hemophilia Factors Market 2022-2026
◆商品コード:IRTNTR72618-22
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2022年6月7日
◆ページ数:約120
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:北米、ヨーロッパ、アジア太平洋、その他地域
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥332,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥399,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥532,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

テクナビオ社は、世界の希少血友病因子市場規模が2022年から2026年まで年平均7.4%成長し、146.76百万ドルに達すると予測しています。本調査レポートは、希少血友病因子の世界市場を調査対象とし、エグゼクティブサマリー、市場状況、市場規模、ファイブフォース分析、手法別(新鮮凍結血漿、濃縮因子、クリオプレシピテート、その他)分析、顧客状況、地域別状況、推進要因・課題・動向、企業状況、企業分析などの項目を掲載しております。本調査レポートでは、Alnylam Pharmaceuticals Inc.、Aptevo Therapeutics Inc.、Bayer AG、Bio Products Laboratory Ltd.、Catalyst Biosciences、Inc.、CSL Ltd.、F. Hoffmann La Roche Ltd.、Genentech Inc.、Grifols SAなどの企業情報が含まれています。
・エグゼクティブサマリー
・市場状況
・市場規模
・ファイブフォース分析
・世界の希少血友病因子市場規模:手法別(新鮮凍結血漿、濃縮因子、クリオプレシピテート、その他)
・顧客状況
・地域別状況
・推進要因・課題・動向
・企業状況
・企業分析

Global Rare Hemophilia Factors Market 2022-2026

Technavio has been monitoring the rare hemophilia factors market and it is poised to grow by $ 146.76 million during 2022-2026, decelerating at a CAGR of 7.4% during the forecast period. Our report on the rare hemophilia factors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by approval of new treatment techniques, introduction of cost-effective and high-quality medical solutions, and favorable government initiatives.
The rare hemophilia factors market analysis includes the method segment and geographic landscape.

Technavio’s rare hemophilia factors market is segmented as below:

By Method
• Fresh frozen plasma
• Factor concentrates
• Cryoprecipitate
• Others

By Geographical Landscape
• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the advent of gene therapy as one of the prime reasons driving the rare hemophilia factors market growth during the next few years. Also, increase in technological innovations and R and D of novel strategies to develop therapeutics will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on rare hemophilia factors market covers the following areas:
• Rare hemophilia factors market sizing
• Rare hemophilia factors market forecast
• Rare hemophilia factors market industry analysis

Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading rare hemophilia factors market vendors that include Alnylam Pharmaceuticals Inc., Aptevo Therapeutics Inc., Bayer AG, Bio Products Laboratory Ltd., Catalyst Biosciences, Inc., CSL Ltd., F. Hoffmann La Roche Ltd., Genentech Inc., Grifols SA, Kedrion Spa, Novo Nordisk, Octapharma AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., The Johns Hopkins Health System Corp., UCSF Health, uniQure NV, Versiti, and Intermountain Healthcare. Also, the rare hemophilia factors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit – https://www.technavio.com/report/rare-hemophilia-factors-market-industry-analysis

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

【資料の目次】

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market Segmentation by Method
o Exhibit 05: Executive Summary – Data Table on Incremental Growth
o Exhibit 06: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 07: Parent market
o Exhibit 08: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 09: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 10: Market segments
o 3.3 Market size 2021
o 3.4 Market outlook: Forecast for 2021-2026
o Exhibit 11: Chart on Global – Market size and forecast 2021-2026 ($ million)
o Exhibit 12: Data Table on Global – Market size and forecast 2021-2026 ($ million)
o Exhibit 13: Chart on Global Market: Year-over-year growth 2021-2026 (%)
o Exhibit 14: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
• 4 Five Forces Analysis
o 4.1 Five forces summary
o Exhibit 15: Five forces analysis – Comparison between 2021 and 2026
o 4.2 Bargaining power of buyers
o Exhibit 16: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
o 4.3 Bargaining power of suppliers
o Exhibit 17: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
o 4.4 Threat of new entrants
o Exhibit 18: Threat of new entrants – Impact of key factors in 2021 and 2026
o 4.5 Threat of substitutes
o Exhibit 19: Threat of substitutes – Impact of key factors in 2021 and 2026
o 4.6 Threat of rivalry
o Exhibit 20: Threat of rivalry – Impact of key factors in 2021 and 2026
o 4.7 Market condition
o Exhibit 21: Chart on Market condition – Five forces 2021 and 2026
• 5 Market Segmentation by Method
o 5.1 Market segments
o Exhibit 22: Chart on Method – Market share 2021-2026 (%)
o Exhibit 23: Data Table on Method – Market share 2021-2026 (%)
o 5.2 Comparison by Method
o Exhibit 24: Chart on Comparison by Method
o Exhibit 25: Data Table on Comparison by Method
o 5.3 Fresh frozen plasma – Market size and forecast 2021-2026
o Exhibit 26: Chart on Fresh frozen plasma – Market size and forecast 2021-2026 ($ million)
o Exhibit 27: Data Table on Fresh frozen plasma – Market size and forecast 2021-2026 ($ million)
o Exhibit 28: Chart on Fresh frozen plasma – Year-over-year growth 2021-2026 (%)
o Exhibit 29: Data Table on Fresh frozen plasma – Year-over-year growth 2021-2026 (%)
o 5.4 Factor concentrates – Market size and forecast 2021-2026
o Exhibit 30: Chart on Factor concentrates – Market size and forecast 2021-2026 ($ million)
o Exhibit 31: Data Table on Factor concentrates – Market size and forecast 2021-2026 ($ million)
o Exhibit 32: Chart on Factor concentrates – Year-over-year growth 2021-2026 (%)
o Exhibit 33: Data Table on Factor concentrates – Year-over-year growth 2021-2026 (%)
o 5.5 Cryoprecipitate – Market size and forecast 2021-2026
o Exhibit 34: Chart on Cryoprecipitate – Market size and forecast 2021-2026 ($ million)
o Exhibit 35: Data Table on Cryoprecipitate – Market size and forecast 2021-2026 ($ million)
o Exhibit 36: Chart on Cryoprecipitate – Year-over-year growth 2021-2026 (%)
o Exhibit 37: Data Table on Cryoprecipitate – Year-over-year growth 2021-2026 (%)
o 5.6 Others – Market size and forecast 2021-2026
o Exhibit 38: Chart on Others – Market size and forecast 2021-2026 ($ million)
o Exhibit 39: Data Table on Others – Market size and forecast 2021-2026 ($ million)
o Exhibit 40: Chart on Others – Year-over-year growth 2021-2026 (%)
o Exhibit 41: Data Table on Others – Year-over-year growth 2021-2026 (%)
o 5.7 Market opportunity by Method
o Exhibit 42: Market opportunity by Method ($ million)
• 6 Customer Landscape
o 6.1 Customer landscape overview
o Exhibit 43: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 7 Drivers, Challenges, and Trends
o 7.1 Market drivers
o 7.2 Market challenges
o 7.3 Impact of drivers and challenges
o Exhibit 44: Impact of drivers and challenges in 2021 and 2026
o 7.4 Market trends
• 8 Vendor Landscape
o 8.1 Overview
o 8.2 Vendor landscape
o Exhibit 45: Overview on Criticality of inputs and Factors of differentiation
o 8.3 Landscape disruption
o Exhibit 46: Overview on factors of disruption
o 8.4 Industry risks
o Exhibit 47: Impact of key risks on business
• 9 Vendor Analysis
o 9.1 Vendors covered
o Exhibit 48: Vendors covered
o 9.2 Market positioning of vendors
o Exhibit 49: Matrix on vendor position and classification
o 9.3 Aptevo Therapeutics Inc.
o Exhibit 50: Aptevo Therapeutics Inc. – Overview
o Exhibit 51: Aptevo Therapeutics Inc. – Product / Service
o Exhibit 52: Aptevo Therapeutics Inc. – Key offerings
o 9.4 Bayer AG
o Exhibit 53: Bayer AG – Overview
o Exhibit 54: Bayer AG – Business segments
o Exhibit 55: Bayer AG – Key news
o Exhibit 56: Bayer AG – Key offerings
o Exhibit 57: Bayer AG – Segment focus
o 9.5 CSL Ltd.
o Exhibit 58: CSL Ltd. – Overview
o Exhibit 59: CSL Ltd. – Business segments
o Exhibit 60: CSL Ltd. – Key offerings
o Exhibit 61: CSL Ltd. – Segment focus
o 9.6 F. Hoffmann La Roche Ltd.
o Exhibit 62: F. Hoffmann La Roche Ltd. – Overview
o Exhibit 63: F. Hoffmann La Roche Ltd. – Business segments
o Exhibit 64: F. Hoffmann La Roche Ltd. – Key news
o Exhibit 65: F. Hoffmann La Roche Ltd. – Key offerings
o Exhibit 66: F. Hoffmann La Roche Ltd. – Segment focus
o 9.7 Grifols SA
o Exhibit 67: Grifols SA – Overview
o Exhibit 68: Grifols SA – Business segments
o Exhibit 69: Grifols SA – Key offerings
o Exhibit 70: Grifols SA – Segment focus
o 9.8 Novo Nordisk
o Exhibit 71: Novo Nordisk – Overview
o Exhibit 72: Novo Nordisk – Business segments
o Exhibit 73: Novo Nordisk – Key offerings
o Exhibit 74: Novo Nordisk – Segment focus
o 9.9 Octapharma AG
o Exhibit 75: Octapharma AG – Overview
o Exhibit 76: Octapharma AG – Product / Service
o Exhibit 77: Octapharma AG – Key offerings
o 9.10 Pfizer Inc.
o Exhibit 78: Pfizer Inc. – Overview
o Exhibit 79: Pfizer Inc. – Product / Service
o Exhibit 80: Pfizer Inc. – Key news
o Exhibit 81: Pfizer Inc. – Key offerings
o 9.11 Sanofi
o Exhibit 82: Sanofi – Overview
o Exhibit 83: Sanofi – Business segments
o Exhibit 84: Sanofi – Key news
o Exhibit 85: Sanofi – Key offerings
o Exhibit 86: Sanofi – Segment focus
o 9.12 Takeda Pharmaceutical Co. Ltd.
o Exhibit 87: Takeda Pharmaceutical Co. Ltd. – Overview
o Exhibit 88: Takeda Pharmaceutical Co. Ltd. – Product / Service
o Exhibit 89: Takeda Pharmaceutical Co. Ltd. – Key news
o Exhibit 90: Takeda Pharmaceutical Co. Ltd. – Key offerings
• 10 Appendix
o 10.1 Scope of the report
o 10.2 Inclusions and exclusions checklist
o Exhibit 91: Inclusions checklist
o Exhibit 92: Exclusions checklist
o 10.3 Currency conversion rates for US$
o Exhibit 93: Currency conversion rates for US$
o 10.4 Research methodology
o Exhibit 94: Research methodology
o Exhibit 95: Validation techniques employed for market sizing
o Exhibit 96: Information sources
o 10.5 List of abbreviations
o Exhibit 97: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market Segmentation by Method
Exhibits5: Executive Summary – Data Table on Incremental Growth
Exhibits6: Executive Summary – Chart on Vendor Market Positioning
Exhibits7: Parent market
Exhibits8: Market Characteristics
Exhibits9: Offerings of vendors included in the market definition
Exhibits10: Market segments
Exhibits11: Chart on Global – Market size and forecast 2021-2026 ($ million)
Exhibits12: Data Table on Global – Market size and forecast 2021-2026 ($ million)
Exhibits13: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibits14: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
Exhibits15: Five forces analysis – Comparison between 2021 and 2026
Exhibits16: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
Exhibits17: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
Exhibits18: Threat of new entrants – Impact of key factors in 2021 and 2026
Exhibits19: Threat of substitutes – Impact of key factors in 2021 and 2026
Exhibits20: Threat of rivalry – Impact of key factors in 2021 and 2026
Exhibits21: Chart on Market condition – Five forces 2021 and 2026
Exhibits22: Chart on Method – Market share 2021-2026 (%)
Exhibits23: Data Table on Method – Market share 2021-2026 (%)
Exhibits24: Chart on Comparison by Method
Exhibits25: Data Table on Comparison by Method
Exhibits26: Chart on Fresh frozen plasma – Market size and forecast 2021-2026 ($ million)
Exhibits27: Data Table on Fresh frozen plasma – Market size and forecast 2021-2026 ($ million)
Exhibits28: Chart on Fresh frozen plasma – Year-over-year growth 2021-2026 (%)
Exhibits29: Data Table on Fresh frozen plasma – Year-over-year growth 2021-2026 (%)
Exhibits30: Chart on Factor concentrates – Market size and forecast 2021-2026 ($ million)
Exhibits31: Data Table on Factor concentrates – Market size and forecast 2021-2026 ($ million)
Exhibits32: Chart on Factor concentrates – Year-over-year growth 2021-2026 (%)
Exhibits33: Data Table on Factor concentrates – Year-over-year growth 2021-2026 (%)
Exhibits34: Chart on Cryoprecipitate – Market size and forecast 2021-2026 ($ million)
Exhibits35: Data Table on Cryoprecipitate – Market size and forecast 2021-2026 ($ million)
Exhibits36: Chart on Cryoprecipitate – Year-over-year growth 2021-2026 (%)
Exhibits37: Data Table on Cryoprecipitate – Year-over-year growth 2021-2026 (%)
Exhibits38: Chart on Others – Market size and forecast 2021-2026 ($ million)
Exhibits39: Data Table on Others – Market size and forecast 2021-2026 ($ million)
Exhibits40: Chart on Others – Year-over-year growth 2021-2026 (%)
Exhibits41: Data Table on Others – Year-over-year growth 2021-2026 (%)
Exhibits42: Market opportunity by Method ($ million)
Exhibits43: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits44: Impact of drivers and challenges in 2021 and 2026
Exhibits45: Overview on Criticality of inputs and Factors of differentiation
Exhibits46: Overview on factors of disruption
Exhibits47: Impact of key risks on business
Exhibits48: Vendors covered
Exhibits49: Matrix on vendor position and classification
Exhibits50: Aptevo Therapeutics Inc. – Overview
Exhibits51: Aptevo Therapeutics Inc. – Product / Service
Exhibits52: Aptevo Therapeutics Inc. – Key offerings
Exhibits53: Bayer AG – Overview
Exhibits54: Bayer AG – Business segments
Exhibits55: Bayer AG – Key news
Exhibits56: Bayer AG – Key offerings
Exhibits57: Bayer AG – Segment focus
Exhibits58: CSL Ltd. – Overview
Exhibits59: CSL Ltd. – Business segments
Exhibits60: CSL Ltd. – Key offerings
Exhibits61: CSL Ltd. – Segment focus
Exhibits62: F. Hoffmann La Roche Ltd. – Overview
Exhibits63: F. Hoffmann La Roche Ltd. – Business segments
Exhibits64: F. Hoffmann La Roche Ltd. – Key news
Exhibits65: F. Hoffmann La Roche Ltd. – Key offerings
Exhibits66: F. Hoffmann La Roche Ltd. – Segment focus
Exhibits67: Grifols SA – Overview
Exhibits68: Grifols SA – Business segments
Exhibits69: Grifols SA – Key offerings
Exhibits70: Grifols SA – Segment focus
Exhibits71: Novo Nordisk – Overview
Exhibits72: Novo Nordisk – Business segments
Exhibits73: Novo Nordisk – Key offerings
Exhibits74: Novo Nordisk – Segment focus
Exhibits75: Octapharma AG – Overview
Exhibits76: Octapharma AG – Product / Service
Exhibits77: Octapharma AG – Key offerings
Exhibits78: Pfizer Inc. – Overview
Exhibits79: Pfizer Inc. – Product / Service
Exhibits80: Pfizer Inc. – Key news
Exhibits81: Pfizer Inc. – Key offerings
Exhibits82: Sanofi – Overview
Exhibits83: Sanofi – Business segments
Exhibits84: Sanofi – Key news
Exhibits85: Sanofi – Key offerings
Exhibits86: Sanofi – Segment focus
Exhibits87: Takeda Pharmaceutical Co. Ltd. – Overview
Exhibits88: Takeda Pharmaceutical Co. Ltd. – Product / Service
Exhibits89: Takeda Pharmaceutical Co. Ltd. – Key news
Exhibits90: Takeda Pharmaceutical Co. Ltd. – Key offerings
Exhibits91: Inclusions checklist
Exhibits92: Exclusions checklist
Exhibits93: Currency conversion rates for US$
Exhibits94: Research methodology
Exhibits95: Validation techniques employed for market sizing
Exhibits96: Information sources
Exhibits97: List of abbreviations



【掲載企業】

Alnylam Pharmaceuticals Inc.、Aptevo Therapeutics Inc.、Bayer AG、Bio Products Laboratory Ltd.、Catalyst Biosciences、Inc.、CSL Ltd.、F. Hoffmann La Roche Ltd.、Genentech Inc.、Grifols SA

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[希少血友病因子のグローバル市場2022-2026:新鮮凍結血漿、濃縮因子、クリオプレシピテート、その他]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆